Avantor, Inc. (NYSE: AVTR) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $10.3B. The Maz Rating grades it against the other companies in its sector.
Avantor, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $15.18, Avantor, Inc. trades at 30.2x trailing earnings, 1.5x sales and 1.8x book value, with an EV/EBITDA of 14.9. Over the last twelve months it generated about $6.7B of revenue and $340M of net income. It runs a gross margin of 31.6%, an operating margin of 7.6% and a net margin of 5.1%. It shows return on equity of 6.0%, return on invested capital of 4.9% and a free cash flow yield of 4.3%. On the balance sheet: a debt-to-equity ratio of 0.63 and a current ratio of 1.89. Over the past 52 weeks the share price ranged from $7.26 to $17.45, with a beta of 0.95.
Avantor, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 8 Buy, 16 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Avantor, Inc. (AVTR) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 35.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.46% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 35.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.46% / 33% · Receivables / Mkt Cap (36m) 10.8% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 35.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.46% / 33.33% · Receivables / Mkt Cap (24m) 10.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 32.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 3.03% / 33.33% · Receivables / Avg Assets (4Q) 9.51% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 31.7% / 33.33% · (Cash+ST Inv) / Total Assets 3.99% / 33.33% · (Cash+Recv) / Total Assets 13.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Avantor, Inc. (AVTR) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. Avantor, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
Avantor, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.